A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Vaccines induce protective immunity by mimicking natural infection without causing disease. Vaccine types include inactivated (killed pathogen), live-attenuated (weakened pathogen), subunit (purified antigen), and mRNA (encoding antigen). Effective vaccines elicit high-affinity, long-lived antibodies and memory T cells through germinal center reactions and drive appropriate Th differentiation.
You already understand immunological memory — the principle that after a first encounter with an antigen, the adaptive immune system generates long-lived memory B cells and memory T cells that respond faster and more powerfully upon re-exposure. Vaccination is the deliberate exploitation of this mechanism: present the immune system with a harmless version of a pathogen's antigens so it builds memory without the patient ever suffering the disease. The secondary response upon actual infection is then so rapid and overwhelming that the pathogen is cleared before it can cause significant harm.
The different vaccine types represent different strategies for presenting antigen safely. Live-attenuated vaccines (measles, MMR, oral polio) use a weakened version of the pathogen that can still replicate but cannot cause serious disease. Because the pathogen replicates, it produces large quantities of antigen over time and triggers both humoral and cellular immunity — these vaccines tend to produce the strongest, most durable responses and often require only one or two doses. The tradeoff is that they cannot be given to immunocompromised patients, since even a weakened pathogen could cause disease when immune defenses are absent. Inactivated vaccines (flu shot, hepatitis A) use killed pathogens that cannot replicate at all, making them safer but generally less immunogenic — they primarily stimulate antibody responses and usually require booster doses.
Subunit vaccines (hepatitis B, HPV) take a more targeted approach: instead of presenting the whole pathogen, they deliver only the specific protein antigens that are most important for protective immunity. This eliminates any risk of infection but also means the immune system sees less antigen diversity. To compensate, subunit vaccines are formulated with adjuvants — substances like aluminum salts or oil-in-water emulsions that activate innate immune pathways and enhance antigen presentation to T cells. Without adjuvants, purified proteins are often too "clean" to trigger the danger signals that dendritic cells need to fully activate adaptive immunity. The newest platform, mRNA vaccines (COVID-19), delivers genetic instructions that cause the patient's own cells to produce the target antigen, combining the antigen presentation advantages of live vaccines with the safety of subunit approaches.
Regardless of platform, an effective vaccine must accomplish two immunological goals. First, it must drive germinal center reactions in lymph nodes, where B cells undergo somatic hypermutation and affinity maturation — the iterative process that produces high-affinity antibodies capable of neutralizing the pathogen. Second, it must generate the right type of T helper response: Th1 polarization for intracellular pathogens like viruses and tuberculosis, Th2 for extracellular parasites. The route of administration, the adjuvant, and the nature of the antigen all influence which T helper subset dominates. This is why vaccine design is not simply about choosing an antigen — it is about engineering the entire immune response, from initial innate activation through memory cell generation, to match the specific threat the pathogen poses.